A novel model based on interleukin 6 and insulin-like growth factor II for detection of hepatocellular carcinoma associated with hepatitis C virus
Tóm tắt
The coexistence of cirrhosis complicates the early detection of hepatocellular carcinoma (HCC). Thus, novel biomarkers for HCC early detection are needed urgently. Traditionally, HCC detection is carried out by evaluating alpha-fetoprotein (AFP) levels combined with imaging techniques. This work aimed to assess interleukin (IL-6) and insulin-like growth factor 2 (IGF 2) as possible HCC markers in comparison to AFP in patients with and without HCC. ROC analysis showed that IGF2 had the highest area under the curve (AUC) for discriminating HCC from liver cirrhosis (0.86), followed by IL6 (0.82), AFP (0.72), and platelet count (0.6). A four-marker model was developed and discriminated HCC from liver cirrhosis with an AUC of 0.97. The best cut-off was 1.28, at which sensitivity and specificity were 90% and 85%, respectively. For small tumor (< 2 cm), the model had an AUC of 0.95 compared to AFP (0.72). Also, the model achieved perfect performance with AUC of 0.93, 0.94, and 0.95 for BCLC (0-A), CLIP (0-1), and Okuda (stage I), respectively, compared to AFP (AUC of 0.71, 0.69, and 0.67, respectively). The four markers may serve as a diagnostic model for HCC early stages and help overcome AFP poor sensitivity.
Tài liệu tham khảo
Ahn JC, Teng PC, Chen PJ, Posadas E, Tseng HR, Lu SC, Yang JD (2020) Detection of circulating tumor cells and their implications as a novel biomarker for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma. Hepatol 73(1):422–436. https://doi.org/10.1002/hep.31165
Parikh ND, Mehta AS, Singal AG, Block T, Marrero JA, Lok AS (2020) Biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 29(12):2495–2503. https://doi.org/10.1158/1055-9965.EPI-20-0005
Rashed WM, Kandeil MA, Mahmoud MO, Ezzat S (2020) Hepatocellular carcinoma (HCC) in Egypt: a comprehensive overview. J Egypt Natl Canc Inst 32(1):1–11. https://doi.org/10.1186/s43046-020-0016-x
Ayuso C, Rimola J, Vilana R, Burrel M, Darnell A, García-Criado Á, Bianchi L, Belmonte E, Caparroz C, Barrufet M, Bruix J, Brú C (2018) Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. Eur J Radiol 101:72–81. https://doi.org/10.1016/j.ejrad.2018.01.025
Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA et al (2018) Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology 154:1706–1718. e1701
Balaceanu LA (2019) Biomarkers vs imaging in the early detection of hepatocellular carcinoma and prognosis. World J Clin Cases 7(12):1367–1382. https://doi.org/10.12998/wjcc.v7.i12.1367
Shiraha H, Iwamuro M, Okada H (2020) Hepatic stellate cells in liver tumor. Adv Exp Med Biol 1234:43–56. https://doi.org/10.1007/978-3-030-37184-5_4
Pavlovic N, Rani B, Gerwins P, Heindryckx F (2019) Platelets as key factors in hepatocellular carcinoma. Cancers 11(7):1022. https://doi.org/10.3390/cancers11071022
Uciechowski P, Dempke WC (2020) Interleukin-6: a Masterplayer in the cytokine network. Oncology 98(3):131–137. https://doi.org/10.1159/000505099
Shakiba E, Ramezani M, Sadeghi M (2018) Evaluation of serum interleukin-6 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis. Clin Exp Hepatol 4(3):182–190. https://doi.org/10.5114/ceh.2018.78122
Yang H, Xuefeng Y, Jianhua X (2020) Systematic review of the roles of interleukins in hepatocellular carcinoma. Clinica Chimica Acta 506:33–43. https://doi.org/10.1016/j.cca.2020.03.001
Adamek A, Kasprzak A (2018) Insulin-like growth factor (IGF) system in liver diseases. Int J Mol Sci 19(5):1308. https://doi.org/10.3390/ijms19051308
Chung H, Kudo M, Takahashi S, Hagiwara S, Sakaguchi Y, Inoue T, Minami Y, Ueshima K, Fukunaga T, Matsunaga T (2008) Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score. J Gastroenterol Hepatol 23(3):445–452. https://doi.org/10.1111/j.1440-1746.2007.05075.x
Chiba T, Suzuki E, Saito T, Ogasawara S, Ooka Y, Tawada A, Iwama A, Yokosuka O (2015) Biological features and biomarkers in hepatocellular carcinoma. World J Hepatol 7(16):2020–2028. https://doi.org/10.4254/wjh.v7.i16.2020
Alqahtani A, Khan Z, Alloghbi A, S Said Ahmed T, Ashraf M, et al. (2019) Hepatocellular carcinoma: molecular mechanisms and targeted therapies. Medicina 55(9):526. https://doi.org/10.3390/medicina55090526
Hin Tang JJ, Hao Thng DK, Lim JJ, Toh TB (2020) JAK/STAT signaling in hepatocellular carcinoma. Hepat Oncol 7(1):HEP18. https://doi.org/10.2217/hep-2020-0001
Refolo MG, Messa C, Guerra V, Carr BI, D’Alessandro R (2020) Inflammatory mechanisms of HCC development. Cancers 12(3):641. https://doi.org/10.3390/cancers12030641
Lou J, Zhang L, Lv S, Zhang C, Jiang S (2017) Biomarkers for hepatocellular carcinoma. Biomark Cancer 9:1–9. https://doi.org/10.1177/1179299X16684640
Ozgor D, Otan E (2020) HCC and tumor biomarkers: does one size fits all? J Gastrointest Cancer 51(4):1122–1126. https://doi.org/10.1007/s12029-020-00485-x
Lokau J, Schoeder V, Haybaeck J, Garbers C (2019) Jak-Stat signaling induced by interleukin-6 family cytokines in hepatocellular carcinoma. Cancers 11(11):1704. https://doi.org/10.3390/cancers11111704
Adnan F, Khan NU, Iqbal A, Ali I, Petruzziello A, Sabatino R, Guzzo A, Loquercio G, Botti G, Khan S, Naeem M, Khan MI (2020) Interleukin-6 polymorphisms in HCC patients chronically infected with HCV. Infect Agent Cancer 15(1):1–7. https://doi.org/10.1186/s13027-020-00285-9
Martinez-Quetglas I, Pinyol R, Dauch D, Torrecilla S, Tovar V, Moeini A, Alsinet C, Portela A, Rodriguez-Carunchio L, Solé M, Lujambio A, Villanueva A, Thung S, Esteller M, Zender L, Llovet JM (2016) IGF2 is up-regulated by epigenetic mechanisms in hepatocellular carcinomas and is an actionable oncogene product in experimental models. Gastroenterology 151(6):1192–1205. https://doi.org/10.1053/j.gastro.2016.09.001
Aleem E, Elshayeb A, Elhabachi N, Mansour AR, Gowily A et al (2012) Serum IGFBP-3 is a more effective predictor than IGF-1 and IGF-2 for the development of hepatocellular carcinoma in patients with chronic HCV infection. Oncol Lett 3(3):704–712. https://doi.org/10.3892/ol.2011.546
Rehem RN, El-Shikh WM (2011) Serum IGF-1, IGF-2 and IGFBP-3 as parameters in the assessment of liver dysfunction in patients with hepatic cirrhosis and in the diagnosis of hepatocellular carcinoma. Hepatogastroenterology 58:949–954
Morace C, Cucunato M, Bellerone R, De Caro G, Crinò S et al (2012) Insulin-like growth factor-II is a useful marker to detect hepatocellular carcinoma? Eur J Intern Med 23(6):e157–e161. https://doi.org/10.1016/j.ejim.2012.04.014
Scheiner B, Kirstein M, Popp S, Hucke F, Bota S, Rohr-Udilova N, Reiberger T, Müller C, Trauner M, Peck-Radosavljevic M, Vogel A, Sieghart W, Pinter M (2019) Association of platelet count and mean platelet volume with overall survival in patients with cirrhosis and unresectable hepatocellular carcinoma. Liver Cancer 8(3):203–217. https://doi.org/10.1159/000489833
Lee CH, Lin YJ, Lin CC, Yen CL, Shen CH, Chang CJ, Hsieh SY (2015) Pretreatment platelet count early predicts extrahepatic metastasis of human hepatoma. Liver Int 35(10):2327–2336. https://doi.org/10.1111/liv.12817
Kubo S, Tanaka H, Shuto T, Takemura S, Yamamoto T, Uenishi T, Tanaka S, Ogawa M, Sakabe K, Yamazaki K, Hirohashi K (2004) Correlation between low platelet count and multicentricity of hepatocellular carcinoma in patients with chronic hepatitis C. Hepatol Res 30(4):221–225. https://doi.org/10.1016/j.hepres.2004.10.005
Attallah AM, Omran MM, Attallah AA, Abdelrazek MA, Farid K, el-Dosoky I (2017) Simplified HCC-ART score for highly sensitive detection of small-sized and early-stage hepatocellular carcinoma in the widely used Okuda, CLIP, and BCLC staging systems. Int J Clin Oncol 22(2):332–339. https://doi.org/10.1007/s10147-016-1066-x
Yu R, Ding S, Tan W, Tan S, Tan Z et al (2015) Performance of protein induced by vitamin k absence or antagonist-II (PIVKA-II) for hepatocellular carcinoma screening in Chinese population. Hepat Mon 15:e28806
Omran MM, Emran TM, Farid K, Eltaweel FM, Omar MA, Bazeed FB (2016) An easy and useful noninvasive score based on α-1-acid glycoprotein and C-reactive protein for diagnosis of patients with hepatocellular carcinoma associated with hepatitis C virus infection. J Immunoassay Immunochem 37(3):273–288. https://doi.org/10.1080/15321819.2015.1132229
Attallah AM, El-Far M, Malak CAA, Omran MM, Shiha GE et al (2015) HCC-DETECT: a combination of nuclear, cytoplasmic, and oncofetal proteins as biomarkers for hepatocellular carcinoma. Tumor Biol 36(10):7667–7674. https://doi.org/10.1007/s13277-015-3501-4
Duarte-Salles T, Misra S, Stepien M, Plymoth A, Muller D, Overvad K, Olsen A, Tjønneland A, Baglietto L, Severi G, Boutron-Ruault MC, Turzanski-Fortner R, Kaaks R, Boeing H, Aleksandrova K, Trichopoulou A, Lagiou P, Bamia C, Pala V, Palli D, Mattiello A, Tumino R, Naccarati A, Bueno-de-Mesquita HB(), Peeters PH, Weiderpass E, Quirós JR, Agudo A, Sánchez-Cantalejo E, Ardanaz E, Gavrila D, Dorronsoro M, Werner M, Hemmingsson O, Ohlsson B, Sjöberg K, Wareham NJ, Khaw KT, Bradbury KE, Gunter MJ, Cross AJ, Riboli E, Jenab M, Hainaut P, Beretta L (2016) Circulating osteopontin and prediction of hepatocellular carcinoma development in a large European population. Cancer Prev Res 9(9):758–765. https://doi.org/10.1158/1940-6207.CAPR-15-0434